Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company’s Strategy to Develop the World’s Largest A.I. Platform for Oncology-Focused Drug Development & Rescue

Apr 29, 2021, 7:00 ET

Read on Cision PR Newswire

  • The growing A.I. platform, which is expected to reach 10 Billion datapoints in the  next 12 months, has been instrumental in uncovering new indications and  potential combination regimens leveraging machine learning algorithms for Lantern’s pipeline of drug candidates 
  • The platform has grown 16-fold over the past 12 months, and 4-fold over the past 4 months — achieving a growth rate of approximately 1 billion data points each month during the first quarter of 2021 
  • The RADR® platform identifies genomically distinct cancer subtypes, provides mechanistic insight about drug-tumor interactions and uncovers patient groups that can respond to specific drugs and compounds that Lantern and its  collaborators are developing 

DALLAS, April 29, 2021 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage  biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to  improve drug discovery and development and identify patients who will benefit from its portfolio  of targeted oncology therapeutics, announced today that RADR® has exceeded 4.6 billion  datapoints. This 16-fold increase in datapoints over the past 12 months was also accompanied  by other significant improvements in the functionality, feature-set and automation of the drug  development platform as well as a significant increase in the number of drugs, drug classes and  cancers covered by RADR®

“We are extremely pleased to share the fact that we have increased the number of biologically  relevant and curated datapoints that power our RADR® platform by 16-fold since last May and  nearly 4-fold since the beginning of the year. The pace of data acquisition, curation, and tagging achieved during this last campaign is well ahead of schedule and allows us to increasingly focus  on building a more complete and more powerful library of algorithms and machine learning models  aimed at rapidly answering questions that are fundamental to oncology drug development,” stated  Panna Sharma, President and CEO of Lantern Pharma. “Our mission to build the world’s largest,  most robust and most accurate A.I. driven platform for precision oncology drug discovery and  development is advancing rapidly. The robustness of the datasets powering RADR® is anticipated  to continue to improve machine-learning results, accelerate automation of other features and aid  oncology drug development for Lantern and our partners with the ultimate focus of benefitting  cancer patients.”

Lantern is committed to growing and enhancing RADR®, which it believes is among the largest  drug development platforms powered exclusively for oncology drug development and rescue. The  growing datapoints, and accompanying functionality in the A.I. platform, allow scientists,  biologists, and engineers to collaborate on issues of drug activity, drug response, patient  stratification, and cancer biomarkers at a pace which has been unachievable, until now. The  developmental focus on increasing the number of datapoints, and improving the performance,  power and biological relevance of the algorithms, is expected to yield additional targeted  indications for Lantern’s current pipeline of drug candidates. We expect that the platform will also  help in revealing additional compounds and therapies that can be in-licensed and subsequently  developed in a more efficient, and potentially more targeted manner. Lantern has used RADR® to uncover indications in multiple cancer sub-types, including CNS (central nervous system)  cancers, drug-resistant lung cancers, lung cancer sub-types among never-smokers and  SMARCB1 mutated cancers (e.g. Atypical Teratoid Rhabdoid Tumors). 

Lantern has filed two additional patent applications directed to the RADR® platform that further  strengthen the Company’s leading position in using A.I. for cancer drug development and drug  rescue. The Company’s patent applications are directed to using machine learning to predict and  discover gene signatures associated with pharmaceutical agents, as well as using automated and  machine learning methods on genomic and biomarker data for rescuing, repurposing and  repositioning of pharmaceutical agents. Lantern expects to continue developing novel A.I. and  machine learning functionality, methods and technologies that it will file patents on both as core  technologies and directed in the use of its pipeline of drug candidates. 

“As A.I. continues to transform drug development, platforms that can provide a machine-learning,  A.I. driven edge are becoming an essential tool for companies to make informed, rapid decisions  in cancer indication selection, trial design, validation of mechanisms and potential creation of  combination therapy regimens,” continued Sharma. “Now, with every major cancer and drug class  being covered in our A.I. platform, Lantern can focus not only on accelerating our portfolio, but  also on developing collaborations that continue to enhance and validate our platform while  delivering insights for our biopharma partners. These RADR® powered insights are expected to  accelerate development timelines, derisk key decisions and uncover new opportunities that may  have gone undeveloped — ultimately leading to oncology therapies that can increase the  personalization of treatment.” 

“Biopharma companies are looking to launch programs in validated indications more rapidly as  they focus on maximizing the potential of each drug candidate,” said Mr. Sharma. “We believe  that RADR® can help design and launch these programs, that continue to grow in complexity, at  a fraction of the cost and timeline of traditional oncology drug development. Creating novel  genomic and mechanistic insights while also providing specific guidance on designing biomarker  driven preclinical studies and clinical trials is an essential component of personalizing cancer treatment. RADR® is a powerful platform that can offer a significant competitive advantage for oncology drug development.”


Marek Ciszewski, JD 

Director, Investor Relations 


About Lantern Pharma 

Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company  leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker  signatures that identify patients most likely to respond to its pipeline of genomically-targeted  therapeutics. Lantern is currently developing four drug candidates and an ADC program across  seven disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients  whose genomic profile identifies them as having the highest probability of benefiting from the  drug, Lantern’s approach represents the potential to deliver best-in-class outcomes. More  information is available at: and Twitter @lanternpharma

Forward-looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the  Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as  amended. These forward-looking statements include, among other things, statements relating to:  future events or our future financial performance; the potential advantages of our RADR® platform  in identifying drug candidates and patient populations that are likely to respond to a drug  candidate; the utilization of our RADR® platform to streamline the drug development process; and  our intention to leverage artificial intelligence, machine learning and genomic data to streamline  and transform the pace, risk and cost of oncology drug discovery and development and to identify  patient populations that would likely respond to a drug candidate. Any statements that are not  statements of historical fact (including, without limitation, statements that use words such as  “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,”  “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the  negative of these words or other similar expressions) should be considered forward-looking  statements. There are a number of important factors that could cause our actual results to differ  materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that no drug product based on our proprietary RADR® A.I.  platform has received FDA marketing approval or otherwise been incorporated into a commercial  product, (iii) the risk that none of our product candidates has received FDA marketing approval,  and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain  marketing approval for our product candidates, and (iv) those other factors set forth in the Risk  Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed  with the Securities and Exchange Commission on March 10, 2021. You may access our Annual  Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab  of our website at or on the SEC’s website at Given these  risks and uncertainties, we can give no assurances that our forward-looking statements will prove  to be accurate, or that any other results or events projected or contemplated by our forward looking statements will in fact occur, and we caution investors not to place undue reliance on  these statements. All forward-looking statements in this press release represent our judgment as  of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update  any forward-looking statements to conform the statement to actual results or changes in our  expectations.

Let’s start a conversation about the future of drug development.

We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.

Contact Us